The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cellmediated cytotoxicity, complement-dependent cytotoxicity, anti-inflammatory functions and serum clearance. In addition, alteration in glycosylation may influence the safety and efficacy of the product. Glycosylation, therefore, is considered as one of the important critical quality attributes of glycoprotein biotherapeutics, and consequently for their biosimilar counterparts. Thus, the carbohydrate moieties of such biopharmaceuticals (both innovator and biosimilar products) should be closely scrutinized during all stages of the manufacturing process. In this paper we introduce a rapid, capillary gel electrophoresis based process to quantitatively assess the glycosylation aspect of biosimilarity (referred to as glycosimilarity) between the innovator and a biosimilar version of etanercept (Enbrel ® and Benepali ® , respectively),
Introduction
Patent expiration on numerous biotherapeutics has created new opportunities for the pharmaceutical industry to develop biosimilars [1] , i.e., versions of the innovative biological products, which are similar but not identical to the innovator product [2] . Most recombinant therapeutic proteins, e.g., monoclonal antibodies, fusion proteins with the Fc fragment of IgG, erythropoietin, etc., and subsequently their biosimilars are possessing various levels of N-glycosylation. Even minor changes in their oligosaccharide structures (linkage, position, and site occupancy) can significantly Abbreviations: APTS, 8-aminopyrene-1,3,6-trisulfonic acid; CGE-LIF, capillary gel electrophoresis -laser induced fluorescence; CQA, critical quality attributes; ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity; Fc, fragment crystallizable; TNF␣, tumor necrosis factor alpha; MOA, mechanism of action.
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influence their safety, efficacy, serum half-life and immunogenicity [3, 4] . Thus, information about the carbohydrate moieties of biosimilars is crucial to properly demonstrate similarity from the glycosylation point of view [5] . Regulatory agencies require comprehensive analysis of all critical quality attributes (CQA) to prove biosimilarity during the development and release of biosimilars, including their glycosylation [2, 6] . This special and important subset of biosimilarity is referred to as glycosimilarity [7] . Adequate determination of glycosimilarity requires proper evaluation of all important carbohydrate associated features like core fucosylation, galactosylation, sialylation and the presence of high mannose structures. The anticipated mechanism of action of a glycoprotein biopharmaceutical assumes appropriate glycosylation, which in turn represents carbohydrate related critical quality attributes [8] . For example, antibody-dependent cell-mediated cytotoxicity (ADCC) requires the absence of core fucosylation at the conserved Fc glycosylation of monoclonal antibodies or fusion proteins with Fc fragments. In the case of complement-dependent cytotoxicity (CDC), antennary galactosylation is an important CQA feature [9] . Mannosylation at the Fc region of monoclonal antibody https://doi.org/10.1016/j.jpba.2018.02.021 0731-7085/© 2018 Elsevier B.V. All rights reserved. therapeutics and IgG fusion proteins enhances clearance, so should be closely monitored during production and release [10] .
Etanercept (Enbrel ® ) was developed to treat Rheumatoid Arthritis and other autoimmune diseases like Psoriasis, Ankylosing Spondylitis, etc. [11] . It is a highly glycosylated IgG Fc fusion protein that binds tumor necrosis factor alpha (TNF␣), a cytokine involved in systemic inflammation [12] . Etanercept possesses three N-glycosylation sites on the TNF␣ receptor part (Asn149, Asn171, and Asn317) and one on the conserved N-linked site of the IgG Fc portion (Asn297). The two parts are connected with a heavily O-glycosylated (13 sites) linker [13] . Since TNF␣ binding represents the mechanism of action of etanercept, Fc function-associated sugar residues like sialylation, core fucosylation or terminal galactosylation are not of high significance from glycosimilarity point of view. Information about the mannosylation level of the product, on the other hand, is important from the perspective of serum half-life [14] . Bioanalytical techniques such as nuclear magnetic resonance spectroscopy, mass spectrometry, slab gel electrophoresis and high-performance liquid chromatography, commonly used for the analysis of complex carbohydrates [15] , are slow and/or offer less than adequate resolution. Capillary electrophoresis is an electric field driven high performance separation technique featuring high separation power and excellent detection limits for oligosaccharides [16] . In this paper we introduce this technique for comparative quantitative characterization of the N-glycosylation and associated glycosimilarity assessment for an innovator biologics fusion protein (Enbrel ® ) and one of its biosimilars (Benepali ® )
using capillary gel electrophoresis with laser induced fluorescent detection.
Materials and methods

Chemicals and reagents
The biopharmaceutical products of Enbrel ® (innovator) and Benepali ® (biosimilar) were kindly provided by the Medical School of University of Debrecen (Debrecen, Hungary). The Fast Glycan Sample Preparation and Analysis kit was from SCIEX (Brea, CA), the PNGase F enzyme from New England Biolabs (Ipswich, MA). The sodium cyanoborohydride (1 M, in THF) and all other chemicals were obtained from Sigma-Aldrich (St Louis, MO).
Sample preparation
The Fast Glycan kit (SCIEX) was used for sample preparation and analysis including fluorophore labeling with 8-aminopyrene-1,3,6-trisulfonic acid (APTS), magnetic bead based sample purification and capillary electrophoresis separation. Briefly, 100 gs of both the innovator and the biosimilar products first underwent PNGase F digestion to liberate their N-glycans, followed by magnetic beadmediated capture of the free oligosaccharides. This was followed by fluorescent labeling of the released carbohydrates with APTS, and another magnetic bead-mediated purification for excess labeling dye removal as reported before in detail [17] . The labeled glycans were then ready for CGE-LIF analysis, or were stored at −20 • C until further processing.
Separation and data analysis
The PA 800 Plus Pharmaceutical Analysis System (SCIEX) used in all separation experiments was equipped with a solid state laser-based fluorescent detector ( ex = 488 nm/ em = 520 nm). The separations were accomplished using either 20 cm (EZ-CE cartridge) or 50 cm effective length (50 m I.D.) bare fused-silica capillary columns, filled with HR-NCHO gel buffer system (SCIEX). 
Results and discussion
Capillary gel electrophoresis with laser-induced fluorescent detection (CGE-LIF) is a fast and efficient method to identify and quantitatively compare N-glycan profiles of biotherapeutics. In this work, we first optimized the separation temperature to obtain the highest resolution among the etanercept N-glycans, then quantitatively compared the released carbohydrates between the originator and the biosimilar products.
Separation temperature optimization
As it has been previously reported, the electromigration properties of carbohydrates are activation energy dependent [18] , thus first the separation temperature was optimized to obtain the highest resolution between the peaks of interest. One of the fastest way of separation temperature optimization in capillary electrophoresis is the application of a temperature gradient [19] . Fig. 1 depicts the separation of the APTS labeled etanercept N-glycans using a temperature gradient from 15 • C to 55 • C. Based on the results, 30 • C separation temperature seemed to be adequate to obtain the required resolution for all 18 carbohydrates of interest, especially between the A2 and Man5 glycans (peaks 7 and 8, respectively), which represent important CQA features. Individual separation temperatures of 25 • C, 30 • C and 35 • C were also evaluated using a 20 cm effective (30 cm total) length capillary tubing to validate the gradient findings of 30 • C optimum (data not shown). 
Comparative CGE-LIF analysis of the N-glycosylation of the innovator and biosimilar products
Next, N-glycan profiles of the innovator biologics, Enbrel ® , and the biosimilar product, Benepali ® , were comparatively analyzed by CGE-LIF at 30 • C using 20 cm separation distance. The resulting electropherograms are shown in Fig. 2 . The lower and upper traces depict the separations of the APTS labeled N-linked oligosaccharides of the two products, respectively. As one can observe, the same peaks were detected in both instances, but with different peak distribution, thus, the different relative amounts were quantitated due to micro-heterogeneity observed. Quantitative assessment was obtained from the relative peak areas and discussed in detail in the next paragraph.
Quantitative glycosimilarity assessment
Quantitative peak distribution changes are visualized in Fig. 3 , where the bars represent the individual glycan structures shown in the X axis corresponding to the originator (dark) and the biosimilar (gray) products. Each bar denotes the average corrected peak areas of 6 runs. Table 1 lists peak identities (numbers correspond to peaks in Fig. 1 ), relative peak area percent values, similarity ratios and similarity percentages (tolerance%). The generally accepted ±20% tolerance window was applied for glycosimilarity assessment [7] . Only peaks with larger than 1% peak area (peaks 1, 2, 5-11, 13, 15-18) were evaluated in this study in respect to glycosimilarity.
The peak areas of all di-and mono-sialo structures complying with the >1% relative peak area criteria (peaks 1, 2, 5, 6 and 9) were smaller in the biosimilar that of in the innovator product. While the di-sialo glycans (peaks 1 and 2) fall out of the 20% tolerance window (−30 and −35%, respectively), the significant mono-sialo products (peaks 6 and 9) were in the range (−16 and −14%, respectively).
Since anti-inflammatory characteristics of these products were no MOA importance, even with the average of ∼33% difference in their abundance did not represent a CQA issue. Similarly, the higher representation of the afucosylated neutral glycans (peaks 7 and 17) found in the biosimilar in comparison to the innovator drug, while well outside of the tolerance window (+63 and +130%, respectively), were not of CQA importance as the ADCC was not an MOA requirement for this product. The largest peak in both electropherograms was the core fucosylated biantennary glycan (FA2, peak 10). This feature was represented in more than 36% in the innovator product than in the biosimilar, however, as CDC was not the MOA, it was not considered in the glycosimilarity assessment. Conversely, the abundance of highly galactosylated glycans (peaks 17 and 18), which were apparently much greater in the biosimilar than in the innovator (+130 and +124%, respectively), did not play a glycosimilarity role either. Interestingly, the peak area differences for the monogalactosylated glycans (peaks 15-16) were very similar and within the tolerance window (+7 and +10%, respectively). This was also true for the high mannose structures (peaks 8 and 11), where the difference between the innovator and biosimilar was below the tolerance window (−13 and +19%, respectively). Due to the fact that mannosylation on the Fc region of therapeutic IgG antibodies as well as Fc fragment containing fusion proteins, such as etanercept, affects the rate of serum clearance in humans, the presence (if any) and the extent of high mannose glycans were deemed as an important critical quality attribute of glycosimilarity prospective.
Conclusions
N-glycosylation plays an essential role in the mechanism of action for most glycoprotein biotherapeutics, thus represents an important CQA subset for biosimilarity. Comprehensive Nglycosylation characterization by capillary gel electrophoresis with laser-induced fluorescent detection (CGE-LIF) provided rapid, highresolution separations with the option of quantitative assessment of the carbohydrates of interest from glycosimilarity point of view. Identification and quantitative comparison of the relative peak areas between the N-glycan profiles of the innovator product (Enbrel ® ) and its biosimilar counterpart (Benepali ® ) were used as a model system to demonstrate glycosimilarity assessment analysis. Albeit, significant quantitative differences were found in sialylated, core-fucosylated and galactosylated structures between the innovator and the biosimilar, since ADCC and CDC functions were not critical to the mechanisms of action of these products, this subset of the data was not considered in glycosimilarity assessment. Mannosylation, on the other hand, plays an important role in serum clearance, so quantification based similarity evaluation of the high mannose structures represented an important CQA, with which, based on our results, this particular biosimilar version of etanercept (Benepali ® ) complied.
